Journal
NEUROBIOLOGY OF DISEASE
Volume 74, Issue -, Pages 144-157Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2014.08.017
Keywords
Alzheimer's disease; A beta seeding-mediated aggregation; A beta-propagation; Amyloid protein; Drug discovery; Inhibitors
Categories
Funding
- Swiss Federal Institute of Technology, Lausanne
- Strauss Foundation
- NIH [AG18440, AG022074, AG031097, AG010435]
Ask authors/readers for more resources
A beta accumulation plays a central role in the pathogenesis of Alzheimer's disease (AD). Recent studies suggest that the process of A beta nucleated polymerization is essential for A beta fibril formation, pathology spreading and toxicity. Therefore, targeting this process represents an effective therapeutic strategy to slow or block disease progression. To discover compounds that might interfere with the A beta seeding capacity, toxicity and pathology spreading, we screened a focused library of FDA-approved drugs in vitro using a seeding polymerization assay and identified small molecule inhibitors that specifically interfered with A beta seeding-mediated fibril growth and toxicity. Mitoxantrone, bithionol and hexachlorophene were found to be the strongest inhibitors of fibril growth and protected primary cortical neuronal cultures against A beta-induced toxicity. Next, we assessed the effects of these three inhibitors in vivo in the mThyl-APPtg mouse model of AD (8-month-old mice). We found that mitoxantrone and bithionol, but not hexachlorophene, stabilized diffuse amyloid plaques, reduced the levels of A beta(42) oligomers and ameliorated synapse loss, neuronal damage and astrogliosis. Together, our findings suggest that targeting fibril growth and A beta seeding capacity constitutes a viable and effective strategy for protecting against neurodegeneration and disease progression in AD. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available